BioAge Labs, Inc. (NASDAQ:BIOA) Receives Average Recommendation of “Moderate Buy” from Brokerages

BioAge Labs, Inc. (NASDAQ:BIOA) has received a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $43.50.

Several equities research analysts have commented on the company. Roth Capital initiated coverage on BioAge Labs in a report on Wednesday, May 27th. They issued a “buy” rating and a $36.00 target price on the stock. Needham & Company LLC started coverage on shares of BioAge Labs in a research report on Friday, March 27th. They set a “buy” rating and a $50.00 price objective on the stock. Wall Street Zen lowered shares of BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Finally, BTIG Research started coverage on shares of BioAge Labs in a research report on Wednesday, May 13th. They set a “buy” rating and a $40.00 price target for the company.

BioAge Labs Price Performance

NASDAQ:BIOA opened at $21.94 on Friday. BioAge Labs has a one year low of $4.11 and a one year high of $25.95. The company’s 50-day simple moving average is $20.11 and its 200 day simple moving average is $19.24. The firm has a market capitalization of $975.23 million, a P/E ratio of -9.14 and a beta of 0.61.

BioAge Labs (NASDAQ:BIOA) last announced its earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. The business had revenue of $2.77 million during the quarter. On average, equities research analysts expect that BioAge Labs will post -2.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioAge Labs

Large investors have recently bought and sold shares of the business. Russell Investments Group Ltd. purchased a new stake in shares of BioAge Labs during the 3rd quarter valued at about $27,000. CWM LLC raised its holdings in shares of BioAge Labs by 39.9% during the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after purchasing an additional 1,053 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after purchasing an additional 5,976 shares during the period. Walleye Capital LLC bought a new position in shares of BioAge Labs during the 2nd quarter valued at $64,000. Finally, Bank of America Corp DE increased its position in BioAge Labs by 46.3% during the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after acquiring an additional 3,517 shares during the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.